http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113194957-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcbc9ca53bc68f405f71764197469b5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 |
| filingDate | 2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0c5cc2230d913de91183234b346ed15 |
| publicationDate | 2021-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113194957-A |
| titleOfInvention | Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators |
| abstract | Disclosed herein are novel methods for preventing hypercoagulopathy, reducing the risk of developing hypercoagulopathy, and treating hypercoagulopathy in Cushing's syndrome patients with an elevated risk of developing hypercoagulopathy. The method can also be used to prevent deep vein thrombosis (DVT), pulmonary embolism (PE) and venous thromboembolism (VTE), reduce the occurrence of deep vein thrombosis (DVT), pulmonary embolism (PE) and venous thromboembolism (VTE) risk and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and treatment of inflammatory states. The method includes administering a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a patient with Cushing's syndrome at risk for developing hypercoagulopathy, thereby treating hypercoagulopathy. A method of preventing DVT, PR or VTE in a patient with Cushing's syndrome, reducing the risk of developing DVT, PR or VTE in a patient with Cushing's syndrome, and treating DVT, PR or VTE in a patient with Cushing's syndrome comprising administering HKGRM to said patient . The method of exposing and subsequently reducing an inflammatory state comprises administering to a patient with Cushing's syndrome an effective amount of HKGRM effective to first increase the patient's inflammatory symptoms and then subsequently reduce the inflammatory symptoms in the patient. |
| priorityDate | 2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 501.